4-氨基-5-甲基噻吩-3-羧酸甲酯 | 81528-48-5

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 4-氨基-5-甲基噻吩-3-羧酸甲酯
• 英文名称: methyl 4-amino-5-methylthiophen-3-carboxylate
• 英文别名: 4-methoxycarbonyl-2-methylthiophene-3-amine；2-methylthiophen-4-methoxycarbonyl-3-amine；methyl 4-amino-5-methylthiophene-3-carboxylate；methyl 2-methyl-3-aminothiophene-4-carboxylate；3-amino-2-methylthiophene-4-carboxylic acid methyl ester；methyl 3-amino-2-methyl-thiophene-4-carboxylate
• CAS: 81528-48-5
• 化学式: C₇H₉NO₂S
• 分子量: 171.22
• InChiKey: IEZNLUYSTWCFIP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4-氨基-5-甲基噻吩-3-羧酸甲酯 在 盐酸 、 sodium nitrite 、 二氧化硫 、 月桂基三甲基溴化铵 、 copper(l) chloride 作用下， 以 水 、 二氯甲烷 为溶剂， 反应 18.0h， 以81%的产率得到4-methoxycarbonyl-2-methylthiophene-3-sulfonyl chloride
  参考文献：
  名称：

  Substituted thien-3-yl-sulphonylamino(thio)carbonyl-triazolin(ethi)ones

  摘要：

  该发明涉及一种新型的取代的噻吩-3-基磺酰胺（硫）羰基三唑林（乙）酮，其通式为（I），其中Q1，Q2，R1，R2，R3和R4均如描述中所定义，并且涉及到公式（I）化合物的盐、制备它们的方法和新的中间体以及它们作为除草剂的用途。

  公开号：

  US20050130843A1
• 作为产物：
  描述：

  methyl 5-methyl-4-oxotetrahydrothiophen-3-carboxylate 在 盐酸羟胺 、 碳酸氢钠 作用下， 以 乙腈 为溶剂， 反应 3.0h， 以48%的产率得到4-氨基-5-甲基噻吩-3-羧酸甲酯
  参考文献：
  名称：

  The Synthesis and Biological Activity of 'Crippled Biotin'

  摘要：

  (3aα,6β,6aα)-6-甲基四氢-1H-噻吩并[3,4-b]吡咯-2(3H)-酮 (2) 作为生物素的残缺类似物被制备出来。合成的关键步骤是在钯上氢化 6-甲基-1H-噻吩并[3,4-b]吡咯-2(3H)-酮，以引入必要的全顺式构型。与底物或该酶的强效除草抑制剂相比，这两种化合物对依赖生物素的小麦乙酰-CoA 羧化酶的抑制作用较弱，但比生物素或咪唑烷酮的抑制作用更强。这两种化合物都不能抑制细菌乙酰-CoA 羧化酶中依赖生物素的转羧化酶成分，也不能显著抑制拟南芥的生长。

  DOI：

  10.1071/ch9951907

文献信息

• Condensed thienopyrimidines. I. Synthesis and gastric antisecretory activity of 2,3-dihydro-5H-oxazolothienopyrimidin-5-one derivatives.
  作者：Mitsuo SUGIYAMA、Toshiaki SAKAMOTO、Keiichi TABATA、Kazuo ENDO、Keiichi ITO、Mitsuko KOBAYASHI、Hiroshi FUKUMI

  DOI：10.1248/cpb.37.2091

  日期：——

  A practical preparation of various 2, 3-dihydro-5H-oxazolo[3, 2-a]thieno[3, 2-d]-, [3, 4-d]-, and [2, 3-d]pyrimidin-5-one derivatives was developed starting from the corresponding aminothiopheneesters in two steps, and their chloro-substituted derivatives were prepared. These compounds were evaluated for gastric antisecretory activity in pylorus-ligated rats, compared to the anti-ulcer standard, cimetidine, and their structure-activity relationships are discussed.

  一种实用的方法被开发用于合成多种2, 3-二氢-5H-噁唑并噻吩的[3, 2-a]、[3, 4-d]和[2, 3-d]嘧啶-5-酮衍生物，该过程从相应的氨基噻吩酯出发，仅需两步，并且其氯取代衍生物也被合成。这些化合物在幽门结扎大鼠中评估了其抗胃分泌活性，并与抗溃疡标准药物西咪替丁进行了比较，同时讨论了它们的结构-活性关系。
• Cardioactive pyrazole and imidazole aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04608383A1

  公开（公告）日：1986-08-26

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamide, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, notro, hydraxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, halomethyl, aminomethyl, lower acylaminomethyl, di(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acyaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them. These compounds are useful for the prophylaxis and combatting of cardiac and circulatory diseases.

  本发明提供了通式为：##STR1##的芳基氧代丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可以相同也可以不同，是氢或卤素原子或较低的烷基、氰基、羧酰胺、羟基、较低的酰氧基、较低的烷氧基、较低的烯基氧基或芳基较低的烷氧基基团，R.sub.5和R.sub.6，可以相同也可以不同，是氢原子或较低的烷基基团，X是含有2至6个碳原子的直链或支链烷基链，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个符号不是氢原子时，也可以是苯基基团，但是当A是尿嘧啶-6-基基团时，尿嘧啶部分的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可以相同也可以不同，是从氢、卤素、硝基、羟胺基、氨基、较低的酰胺基、较低的烷基氨基、二(较低烷基)氨基、羟乙基氨基、二(羟乙基)氨基、羟基、较低的烷氧基、烯丙氧基、甲氧基较低的烷氧基、氰基、羧酰胺基、羧基、较低的烷氧羰基、羟甲基、较低的烷氧甲基、卤甲基、氨基甲基、较低的酰氨基甲基、卤甲基、氨基甲基、较低的酰氨基甲基、二(较低烷基)-氨基甲基、吡咯烷甲基、哌啶甲基、二(羟乙基)-氨基甲基、吡咯啉甲基、哌嗪甲基、4-较低的酰基哌嗪甲基、4-较低的烷基哌嗪甲基、较低的烷基、较低的烯基、2-氰基乙基、2-羟基乙基、苯基较低的烷基和苯基等单价或二价取代基，其中苯基基团可以选择性地取代1或2个羟基或甲氧基基团，或者从氧或硫；其光学活性形式和外消旋混合物，以及其药理兼容盐。本发明还提供了制备这些化合物的方法和含有它们的药物组合物。这些化合物对于预防和治疗心脏和循环疾病非常有用。
• Cardioactive aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04438128A1

  公开（公告）日：1984-03-20

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamido, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, nitro, hydroxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-(lower alkoxycarbonyl)-ethyl, 2-carboxyethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.

  本发明提供了通式为：##STR1##的芳氧基丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可以相同也可以不同，是氢原子或卤素原子或较低的烷基、氰基、羧胺基、羟基、较低的酰氧基、较低的烷氧基、较低的烯氧基或芳基较低的烷氧基基团，R.sub.5和R.sub.6，可以相同也可以不同，是氢原子或较低的烷基基团，X是含有2至6个碳原子的直链或支链烷基链，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个符号不是氢原子时，也可以是苯基基团，但前提是当A是尿嘧啶-6-基基团时，尿嘧啶部分的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可以相同也可以不同，是从氢、卤素、硝基、羟胺基、氨基、较低的酰氨基、较低的烷基氨基、二(较低的烷基)-氨基、羟乙基氨基、二(羟乙基)-氨基、羟基、较低的烷氧基、烯丙氧基、甲氧基较低的烷氧基、氰基、羧胺基、羧基、较低的烷氧羰基、羟甲基、较低的烷氧甲基、卤甲基、氨基甲基、较低的酰胺基甲基、二(较低的烷基)-胺基甲基、吡咯烷基甲基、哌啶基甲基、二(羟乙基)-胺基甲基、吗啉基甲基、哌嗪基甲基、4-较低的酰基哌嗪基甲基、4-较低的烷基哌嗪基甲基、较低的烷基、较低的烯基、2-氰基乙基、2-(较低的烷氧羰基)-乙基、2-羧基乙基、2-羟基乙基、苯基较低的烷基和苯基中的苯基，苯基基团可以选择性地用1或2个羟基或甲氧基基团取代，或者用氧或硫替代；其光学活性形式和其外消旋混合物，以及其药理相容的盐。本发明还提供了制备这些化合物的方法和含有它们的药物组合物。
• Condensed thienopyrimidines. II. Synthesis and gastric antisecretory activity of thiazole and polymethylene condensed thienopyrimidine derivatives.
  作者：Mitsuo SUGIYAMA、Toshiaki SAKAMOTO、Keiichi TABATA、Kazuo ENDO、Keiichi ITO、Mitsuko KOBAYASHI、Hiroshi FUKUMI

  DOI：10.1248/cpb.37.2122

  日期：——

  Thiazolo[3, 2-a]thieno[3, 2-d]-, [3, 4-d]- and [2, 3-d]pyrimidin-5-one derivatives (6, 11, and 16), and polymethylene condensed thieno[3, 2-d]-, [3, 4-d]- and [2, 3-d]pyrimidin-5-one derivatives (19-21), in which the oxygen atom of the oxazolidine moiety in 3 was replaced by a sulfur atom or methylene groups, were synthesized and evaluated for gastric antisecretory activity in pylorus-ligated rats. The structure-activity relationships of these compounds are discussed.

  合成并评估了噻唑并噻吩和嘧啶-5-酮衍生物（6、11和16）以及多亚甲基缩合的噻吩-和嘧啶-5-酮衍生物（19-21），其中在3的噁唑烷环中的氧原子被硫原子或亚甲基取代，并对在幽门结扎大鼠中进行的胃抗分泌活性进行了评估。文中讨论了这些化合物的结构-活性关系。
• Atroposelective Ring Opening of Cyclic Diaryliodonium Salts with Bulky Anilines Controlled by a Chiral Cobalt(III) Anion
  作者：Xue Zhang、Kun Zhao、Na Li、Jie Yu、Liu‐Zhu Gong、Zhenhua Gu

  DOI：10.1002/anie.202008431

  日期：2020.11.2

  The present work demonstrates a CuCl and anionic chiral cobalt(III)‐catalyzed enantioselective ring‐opening reaction. The small‐size, ligand‐free copper species enabled the cross‐coupling of iodonium salts with a series of bulky aromatic amines in high ee values. The chiral cobalt(III) anion causes appreciable chemical shift changes of cyclic diaryliodoniums in 1H NMR spectra.

  本工作证明了CuCl和阴离子手性钴（III）催化的对映选择性开环反应。小尺寸，无配体的铜物质使碘鎓盐与一系列高ee值的笨重芳族胺交叉偶联。手性钴（III）阴离子在1 H NMR光谱中引起环状二芳基碘鎓的明显化学位移变化。